Stocks · News reference
Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 8:05 PM
- Checked
- Aug 10, 2026, 8:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — ENANTA PHARMACEUTICALS INC (ENTA)
Filed: 2026-07-02 AccNo: 0001193125-26-294837 Size: 426 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Read original at edgar'Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral' - Bloomberg
Read original at benzinga